Furthermore, oncogenic YAP1 activation occurs as a consequence of a loss in NF2-dependent inactivation of LATS1 (a key inhibitor of YAP1), and decreased LATS1 activity has also been associated with glioma progression (Ji et al. 2012; Oh et al. 2015; Shi et al. 2016). Here, YAP1 is linked to glioma.